FindMyKOL
Clinical trialNCT00133679TerminatedPhase 4Interventional

Chronic Sildenafil for Severe Diaphragmatic Hernia

NCT00133679 is a phase 4 interventional trial sponsored by University of California, San Francisco. As of 18 Nov 2026, it was terminated. It studies Placebo and Sildenafil in Hernia, Diaphragmatic, Hypertension, Pulmonary and 1 more condition. The registry lists an enrollment of 9 participants at 3 sites in 1 country. The registry lists a start date of 28 Feb 2006 and a primary completion date of 31 Jul 2013.

SponsorUniversity of California, San Francisco →Enrollment9Hernia, DiaphragmaticHypertension, PulmonaryHypoplasia, Pulmonary
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00133679
FieldValue
Registry IDNCT00133679
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorUniversity of California, San Francisco
Enrollment9
Registered sites3
Countries1
ConditionsHernia, Diaphragmatic, Hypertension, Pulmonary and Hypoplasia, Pulmonary
DrugsPlacebo and Sildenafil
Start28 Feb 2006
Primary completion31 Jul 2013
Study completion31 Oct 2013
Last update posted13 Jan 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test if sildenafil is effective in the treatment of infants with severe congenital diaphragmatic hernia (determined by the presence of prolonged pulmonary hypertension or prolonged oxygen supplementation on mechanical ventilation), as measured by the estimated pulmonary artery systolic pressure following treatment.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites
  • Children's Hospital of Los Angeles

    Los Angeles

  • University of California San Francisco Children's Hospital

    San Francisco

Illinois, United States1 site
  • Children's Memorial Hospital

    Chicago

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00133679

Each answer restates registry values shown on this page.

What is NCT00133679?

NCT00133679 is a phase 4 interventional trial sponsored by University of California, San Francisco. It studies Placebo and Sildenafil in Hernia, Diaphragmatic, Hypertension, Pulmonary and 1 more condition.

Who leads NCT00133679?

The registry names Roberta L Keller, MD (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT00133679 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00133679 study?

The registered drug and biological interventions are Placebo and Sildenafil.

When did NCT00133679 end?

The registry lists a primary completion date of 31 Jul 2013 and a study completion date of 31 Oct 2013. The sponsor last updated the record on 13 Jan 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.